US-based clinical-stage biotechnology company SystImmune, Inc announced on Monday that it has received US Food and Drug Administration clearance for its Investigational New Drug application for BL-M11D1, an antibody-drug conjugate targeting CD33 on myeloid cells.
This approval supports the launch of a Phase 1 clinical trial, BLM11D1-HM-101, to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of BL-M11D1 in patients with relapsed or refractory Acute Myeloid Leukemia.
Dr Jonathan Cheng, CMO at SystImmune, said that receiving the FDA Study-May-Proceed letter enables the initiation of our Phase 1 study with BL-M11D1, we believe that this novel, potentially best-in-class ADC can offer an important therapeutic option for patients with relapsed/refractory AML and look forward to implementing this study.
BL-M11D1 combines a CD33-binding monoclonal antibody with a topoisomerase I inhibitor, linked by a stable enzyme-cleavable linker. Upon binding to CD33, BL-M11D1 induces antibody-dependent cellular cytotoxicity and releases its cytotoxic payload, killing the tumour cells. FDA clearance marks a significant milestone in advancing SystImmune's clinical pipeline.
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Frost & Sullivan honours Novotech
Turnstone Biologics announces strategic restructuring
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Novo Holdings launches Booster Therapeutics
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
KeyBioscience extends Eli Lilly collaboration
Tempest to advance amezalpat combination into pivotal trial for HCC
Pharming initiates Phase II clinical trial for leniolisib in PIDs
NeuroSense Therapeutics pursues early commercialisation of ALS treatment in Canada
Biogen receives FDA Breakthrough Therapy Designation for felzartamab